Updates in Chronic Lymphocytic Leukemia: 10 Years of Paradigm Change and Outlook for the Future
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 46
Special Issue Editor
Special Issue Information
Dear Colleagues,
Chronic lymphocytic leukemia (CLL) is the most prevalent blood cancer in the Western world. Up to a decade ago, patients in need of therapy only had chemotherapy and monoclonal antibodies available. The year 2014 marked a watershed moment in the history of CLL, with the approval of ibrutinib. The availability of targeted drugs changed the landscape of CLL and, since the approval of ibrutinib, seven other novel drugs were approved for the treatment of CLL (with some currently removed from use).
This Special Issue marks 10 years since novel agents for CLL have been available for use outside of clinical trials. Much knowledge has been acquired during the past decade and now we look to the future with the following aims: understanding mechanisms of resistance, evaluating treatments for patients with disease that is refractory to the currently available drugs, and focusing on minimizing toxicity and improving quality of life for our patients.
We invite you to submit an article to this Special Issue, where we aim to highlight where we stand in the treatment of CLL and what our path is moving forward. We thank you in advance for your contribution.
Dr. Alan Skarbnik
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic lymphocytic leukemia
- treatment
- targeted therapy
- chemotherapy
- treatment resistance
- quality of life
